AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23479253 — intervention group
Group type: COMPARATOR
Intervention: Discovery Learning (DL)
Number of subjects: 36
Study 20953418 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (manual and/or electro-stimulation)
Number of subjects: 333
Study 20953418 — intervention group
Group type: COMPARATOR
Intervention: No treatment, sham procedure, or usual biomedical care
Number of subjects: 333
Study 19008099 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training and guided imagery
Number of subjects: 80
Study 17457567 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-hole titanium compression plate for ulna shortening osteotomy
Number of subjects: 70
Study 15081441 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 499
Study 15081441 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 499
Study 11203780 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable composite (Protect Liner F)
Number of subjects: 25
Study 11203780 — intervention group
Group type: COMPARATOR
Intervention: Control group (without flowable composite)
Number of subjects: 25
Study 11203780 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional enamel etching with 37% phosphoric acid gel (K-etchant)
Number of subjects: 25
Study 11203780 — intervention group
Group type: COMPARATOR
Intervention: Control group (without additional enamel etching)
Number of subjects: 25
Study 15168719 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug combinations of stavudine (d4T), lamivudine (3TC), and indinavir
Number of subjects: 0
Study 15168719 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug combinations of d4T, didanosine (ddI), and indinavir
Number of subjects: 0
Study 15168719 — intervention group
Group type: COMPARATOR
Intervention: Three-drug combinations of zidovudine (ZDV), 3TC, and indinavir
Number of subjects: 0
Study 15168719 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-drug combinations of d4T and 3TC
Number of subjects: 0
Study 15168719 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-drug combinations of d4T and ddI
Number of subjects: 0
Study 15168719 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-drug combinations of ZDV and 3TC
Number of subjects: 0
Study 15168719 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-drug combinations of ZDV and ddI
Number of subjects: 0
Study 7808748 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg daily for 3 weeks)
Number of subjects: 41
Study 7808748 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 tablet daily for 8-10 days)
Number of subjects: 41
Study 2753659 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultory percussion
Number of subjects: 100
Study 2753659 — intervention group
Group type: COMPARATOR
Intervention: Conventional chest percussion
Number of subjects: 100
Study 787013 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional gingivectomy
Number of subjects: 28
Study 787013 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical regime (scaling and oral hygiene instruction)
Number of subjects: 28
Study 30923105 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine
Number of subjects: 0
Study 30923105 — intervention group
Group type: COMPARATOR
Intervention: Postremission observation
Number of subjects: 0
Study 28609330 — intervention group
Group type: EXPERIMENTAL
Intervention: Fan use
Number of subjects: 18
Study 25956718 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive RBC transfusion policy (transfusion when haemoglobin concentration fell below 80 g/L)
Number of subjects: 936
Study 25956718 — intervention group
Group type: COMPARATOR
Intervention: Liberal RBC transfusion policy (transfusion when haemoglobin concentration fell below 100 g/L)
Number of subjects: 936
Study 25956718 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both policies
Number of subjects: 936
Study 23364005 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g n-3 PUFA-containing lipid (70% EPA plus 10% DHA) daily for 3 months
Number of subjects: 79
Study 23364005 — intervention group
Group type: COMPARATOR
Intervention: Control lipid
Number of subjects: 79
Study 21050681 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopped smoking at 1 year
Number of subjects: 1185
Study 20224148 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic-added formula (0.8 g/dl of a mixture from scGOS and lcFOS, ratio 9:1)
Number of subjects: 49
Study 20224148 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic-added formula (L. reuteri at dose of 1x10(8) CFU per day)
Number of subjects: 49
Study 20224148 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 49
Study 20224148 — intervention group
Group type: COMPARATOR
Intervention: Placebo formula
Number of subjects: 49
Study 17263930 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment algorithm for hypertension
Number of subjects: 1534
Study 17263930 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1534
Study 15482078 — intervention group
Group type: EXPERIMENTAL
Intervention: Musical mood induction procedures (MMIP) in a negative mood condition for CM drinkers
Number of subjects: 86
Study 15482078 — intervention group
Group type: EXPERIMENTAL
Intervention: Musical mood induction procedures (MMIP) in a positive mood condition for EM drinkers
Number of subjects: 86
Study 15482078 — intervention group
Group type: COMPARATOR
Intervention: Positive mood condition (control)
Number of subjects: 86
Study 15482078 — intervention group
Group type: COMPARATOR
Intervention: Negative mood condition (control)
Number of subjects: 86
Study 11678953 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure applied to nasal mucosa
Number of subjects: 10
Study 11678953 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (10 and 80 nmol/mL) applied to nasal mucosa
Number of subjects: 10
Study 11678953 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline (1 : 1000) applied to nasal mucosa
Number of subjects: 10
Study 11678953 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied to nasal mucosa
Number of subjects: 10
Study 9759745 — intervention group
Group type: EXPERIMENTAL
Intervention: School mental-health programme (4-month duration)
Number of subjects: 400
Study 9759745 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 400
Study 8782976 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with one antiepileptic drug
Number of subjects: 0
Study 8782976 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with another antiepileptic drug
Number of subjects: 0
Study 2200253 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine alone
Number of subjects: 12
Study 2200253 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate plus nifedipine
Number of subjects: 12
Study 2200253 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate alone
Number of subjects: 12
Study 6454598 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic erythromycin stearate
Number of subjects: 56
Study 6454598 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 56
Study 30719933 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinpro 5000
Number of subjects: 120
Study 30719933 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinpro Tooth Crème
Number of subjects: 120
Study 30719933 — intervention group
Group type: EXPERIMENTAL
Intervention: MI Paste Plus
Number of subjects: 120
Study 28969592 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision aid
Number of subjects: 397
Study 25450131 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipath NMES
Number of subjects: 20
Study 25450131 — intervention group
Group type: COMPARATOR
Intervention: Conventional NMES
Number of subjects: 20
Study 24064440 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endobronchial and endoscopic ultrasound followed by surgical staging if endoscopy was negative
Number of subjects: 0
Study 24064440 — intervention group
Group type: COMPARATOR
Intervention: Surgical staging alone
Number of subjects: 0
Study 23145548 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐efficient experimental design
Number of subjects: 0
Study 23145548 — intervention group
Group type: COMPARATOR
Intervention: Orthogonal experimental design
Number of subjects: 0
Study 20636243 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg intravaginal misoprostol every 6 hours for a maximum of four doses
Number of subjects: 240
Study 20636243 — intervention group
Group type: COMPARATOR
Intervention: 14-F Foley catheter plus intravenous oxytocin initiated after balloon extrusion or after 24 hours
Number of subjects: 240
Study 18413703 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine alone (10‐40 mg/day)
Number of subjects: 439
Study 18413703 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT alone
Number of subjects: 439
Study 18413703 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT combined with fluoxetine (10‐40 mg/day)
Number of subjects: 439
Study 18413703 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivalent to 10‐40 mg/day)
Number of subjects: 439
Study 15837247 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (TAXUS stent)
Number of subjects: 1314
Study 15837247 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (control)
Number of subjects: 1314
Study 15837247 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (TAXUS stent) in proximal LAD subgroup
Number of subjects: 1314
Study 15837247 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (control) in proximal LAD subgroup
Number of subjects: 1314
Study 11844743 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 11844743 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0
Study 11844743 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 0
Study 11844743 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin
Number of subjects: 0
Study 11844743 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antiresorptive therapies
Number of subjects: 0
Study 11844743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10357325 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 6 microg/kg orally 120 min before anesthesia and 3 microg/kg IV over the final hour of surgery
Number of subjects: 20
Study 10357325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8817265 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled, tangential load-forces delivered in an unpredictable manner to the grip surface in contact with the index finger
Number of subjects: 0
Study 8817265 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal loads (away from the palm)
Number of subjects: 0
Study 8817265 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal loads (toward the palm)
Number of subjects: 0
Study 8817265 — intervention group
Group type: EXPERIMENTAL
Intervention: Loads in the direction of gravity
Number of subjects: 0
Study 8817265 — intervention group
Group type: EXPERIMENTAL
Intervention: Different hand positions (standard, inverted, horizontally rotated)
Number of subjects: 0
Study 1445474 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug groups
Number of subjects: 103
Study 1445474 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 103
Study 2578649 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity-sensing, rate-responsive pacing (A)
Number of subjects: 6
Study 2578649 — intervention group
Group type: COMPARATOR
Intervention: Fixed rate demand pacing (D)
Number of subjects: 6
Study 31658058 — intervention group
Group type: COMPARATOR
Intervention: Hydromethylthionine at 8 mg/day (control dose)
Number of subjects: 1686
Study 31658058 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromethylthionine at higher doses (4-21 ng/ml)
Number of subjects: 1686
Study 31658058 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromethylthionine at 16 mg/day (predicted optimal dose)
Number of subjects: 1686
Study 29319386 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education (PNE) and shoulder/neck exercises
Number of subjects: 43
Study 29319386 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 43
Study 25750519 — intervention group
Group type: EXPERIMENTAL
Intervention: Test drug (tramadol formulation)
Number of subjects: 0
Study 24211751 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 76
Study 24211751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 21675059 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily sedation interruption
Number of subjects: 699
Study 21675059 — intervention group
Group type: COMPARATOR
Intervention: No sedation interruption
Number of subjects: 699
Study 19319008 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based vergence/accommodative therapy
Number of subjects: 0
Study 19319008 — intervention group
Group type: EXPERIMENTAL
Intervention: Base-in prism reading glasses
Number of subjects: 0
Study 19319008 — intervention group
Group type: COMPARATOR
Intervention: Home-based therapy (pencil push-ups)
Number of subjects: 0
Study 19319008 — intervention group
Group type: COMPARATOR
Intervention: Office-based placebo therapy
Number of subjects: 0
Study 18001519 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (4.6 mg/24 hour, 5 cm²)
Number of subjects: 0
Study 18001519 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (9.5 mg/24 hour, 10 cm²)
Number of subjects: 0
Study 18001519 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine capsules (3 mg BID, 6 mg/day)
Number of subjects: 0
Study 18001519 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine capsules (6 mg BID, 12 mg/day)
Number of subjects: 0
Study 14734002 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 micrograms of D17DT
Number of subjects: 12
Study 14734002 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 micrograms of D17DT
Number of subjects: 12
Study 11137809 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve replacement with posterior chordal preservation
Number of subjects: 56
Study 11137809 — intervention group
Group type: COMPARATOR
Intervention: Mitral valve replacement with chordal transection
Number of subjects: 56
Study 8419555 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine, 1.25 mg, three times per day for two weeks
Number of subjects: 29
Study 8419555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 3532784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular fitness training
Number of subjects: 34
Study 3532784 — intervention group
Group type: COMPARATOR
Intervention: Flexibility exercises (Control)
Number of subjects: 34
Study 27974550 — intervention group
Group type: EXPERIMENTAL
Intervention: HM‐JACKarc
Number of subjects: 48888
Study 27974550 — intervention group
Group type: COMPARATOR
Intervention: OC‐Sensor
Number of subjects: 48888
Study 25193822 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanochemical ablation (ClariVein®)
Number of subjects: 119
Study 25193822 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (Covidien® Venefit™)
Number of subjects: 119
Study 25193822 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 119
Study 25020155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (2-session intervention aimed at increasing adherence)
Number of subjects: 62
Study 25020155 — intervention group
Group type: COMPARATOR
Intervention: Control (similar levels of non-medication-related contact)
Number of subjects: 62
Study 23635728 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (500 mg, three times daily)
Number of subjects: 187
Study 23635728 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg, three times daily)
Number of subjects: 187
Study 23635728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 21068481 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta 10,000 IU thrice weekly (TW)
Number of subjects: 100
Study 21068481 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta 30,000 IU once weekly (OW)
Number of subjects: 100
Study 21068481 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta therapy (both schedules)
Number of subjects: 100
Study 18191071 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline characteristics (demographics, medical history, anthropometry)
Number of subjects: 5145
Study 18191071 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographics and medical history
Number of subjects: 5145
Study 18191071 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable analysis
Number of subjects: 5145
Study 17190179 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 31
Study 14987200 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSCT
Number of subjects: 56
Study 14987200 — intervention group
Group type: COMPARATOR
Intervention: BMT
Number of subjects: 56
Study 10933122 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood Uniform Assessment Package (CUAP)
Number of subjects: 250
Study 10933122 — intervention group
Group type: COMPARATOR
Intervention: Routine assessment and treatment as usual (ATU)
Number of subjects: 250
Study 8959163 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 sutures
Number of subjects: 10
Study 8959163 — intervention group
Group type: COMPARATOR
Intervention: 2 staples
Number of subjects: 10
Study 8959163 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 staples
Number of subjects: 10
Study 1573032 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranylcypromine (TCP) 30 mg (target dose), actual mean dose 18.5 mg
Number of subjects: 0
Study 1573032 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMI) 150 mg (target dose), actual mean dose 114.3 mg
Number of subjects: 0
Study 1573032 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of TCP and AMI (target doses: TCP 30 mg, AMI 150 mg; actual mean doses: TCP 19.7 mg, AMI 108.7 mg)
Number of subjects: 0
Study 1573032 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 3523369 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically administered alpha‐adrenoceptor agonist (phenylpropanolamine)
Number of subjects: 10
Study 3523369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30143396 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-controlled delivery system
Number of subjects: 76
Study 30143396 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 76
Study 27439227 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling sessions with a therapist utilizing motivational interviewing techniques
Number of subjects: 204
Study 27439227 — intervention group
Group type: COMPARATOR
Intervention: Printed educational materials
Number of subjects: 204
Study 23523540 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency vibration training (32 Hz, 1mm, 4 g)
Number of subjects: 50
Study 23523540 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency vibration training (18 Hz, 3 mm, 4 g)
Number of subjects: 50
Study 23523540 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vibration training)
Number of subjects: 50
Study 22774940 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Health Assessment Program (CHAP)
Number of subjects: 46
Study 21977860 — intervention group
Group type: EXPERIMENTAL
Intervention: Zishengukang Pill with Western medicine
Number of subjects: 64
Study 21977860 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 64
Study 19111362 — intervention group
Group type: EXPERIMENTAL
Intervention: PTV(4D)
Number of subjects: 10
Study 19111362 — intervention group
Group type: EXPERIMENTAL
Intervention: PTV(3CT)
Number of subjects: 10
Study 19111362 — intervention group
Group type: COMPARATOR
Intervention: PTV(conv)
Number of subjects: 10
Study 16927568 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS-Methylphenidate (OROS-MPH, Concerta)
Number of subjects: 213
Study 16927568 — intervention group
Group type: COMPARATOR
Intervention: IR-Methylphenidate (IR-MPH)
Number of subjects: 213
Study 15314810 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular diastolic function (restrictive filling pattern)
Number of subjects: 520
Study 15314810 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular systolic function
Number of subjects: 520
Study 15314810 — intervention group
Group type: EXPERIMENTAL
Intervention: History of systemic hypertension, wall motion score index (WMSi), history of previous MI, diabetes mellitus
Number of subjects: 520
Study 15314810 — intervention group
Group type: EXPERIMENTAL
Intervention: History of systemic hypertension, congestive heart failure
Number of subjects: 520
Study 15314810 — intervention group
Group type: EXPERIMENTAL
Intervention: History of systemic hypertension, wall motion score index, diabetes mellitus
Number of subjects: 520
Study 11738228 — intervention group
Group type: EXPERIMENTAL
Intervention: WARIS‐II
Number of subjects: 0
Study 11738228 — intervention group
Group type: EXPERIMENTAL
Intervention: ESCAMI
Number of subjects: 0
Study 11738228 — intervention group
Group type: EXPERIMENTAL
Intervention: PAFAC
Number of subjects: 0
Study 11738228 — intervention group
Group type: EXPERIMENTAL
Intervention: RITZ‐I
Number of subjects: 0
Study 11738228 — intervention group
Group type: EXPERIMENTAL
Intervention: TIME
Number of subjects: 0
Study 9310720 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF)
Number of subjects: 0
Study 9310720 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone acetate 0.5% (Cortaid Cream)
Number of subjects: 0
Study 9310720 — intervention group
Group type: COMPARATOR
Intervention: Clobetasone butyrate 0.05% (Eumovate Cream)
Number of subjects: 0
Study 9310720 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol propionate 0.05% (Clobesol Cream)
Number of subjects: 0
Study 7870986 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum for 1 month
Number of subjects: 128
Study 7870986 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum for 3 months
Number of subjects: 128